Idt Biologika Sustainability Profile
Idt Biologika, a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across Europe and Asia. Founded in 1991, the company has established itself as a leader in the development and manufacturing of vaccines, biologics, and sterile injectables. Idt Biologika is renowned for its innovative approach to contract development and manufacturing, offering unique solutions that cater to the specific needs of its clients. The company’s state-of-the-art facilities and commitment to quality have positioned it as a trusted partner in the global market. With a focus on advancing public health, Idt Biologika has achieved significant milestones, including collaborations with major pharmaceutical companies and contributions to vaccine development. Its dedication to excellence and innovation continues to drive its success in the competitive biopharmaceutical landscape.
DitchCarbon Score
How does Idt Biologika's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Idt Biologika's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Idt Biologika's reported carbon emissions
In 2024, IDT Biologika reported total carbon emissions of approximately 8,808,950 kg CO2e from Scope 1 sources, primarily from stationary combustion, and about 6,369,670 kg CO2e from Scope 2 emissions. This marks a slight increase in Scope 1 emissions compared to 2023, where emissions were about 8,419,330 kg CO2e for Scope 1 and approximately 7,209,210 kg CO2e for Scope 2. The company has committed to achieving net-zero emissions across all scopes by 2050, with a near-term target status of "Committed" as of May 2024. This commitment is part of their alignment with the Science Based Targets initiative (SBTi), which underscores their long-term climate strategy. IDT Biologika's emissions data is cascaded from its parent company, IDT Biologika GmbH, reflecting its corporate family relationship. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector, and its climate commitments are crucial for addressing the industry's environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 8,443,450 | 0,000,000 | 0,000,000 |
| Scope 2 | 12,228,900 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Idt Biologika's Industry?
How Carbon Intensive is Idt Biologika's Location?
Idt Biologika's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Idt Biologika has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Frequently Asked Questions
Common questions about Idt Biologika's sustainability data and climate commitments